Cardiac rhythm management (CRM) comprises any method of treatment aimed at regulating the heart’s rhythm, including medication, medical devices, and occasionally surgery. There can be a number of reasons why CRM is needed, all of which generally involve malfunctions of the heart’s electrical system, and are related to cardiac dyssynchrony. While medication can be effective in mild to moderate cases, patients with more severe conditions must turn to device use or surgical intervention in order to receive the therapy they require. Over the years, CRM device treatment has become less invasive, and significant advances in pacing and pulse generator technology have enabled effective long-term device therapy with limited complications.
Questions Answered in this Report
Around the world, dual-chamber pacemakers and ICDs are increasingly popular, which is one of the major factors in driving up the costs of the devices. What is the breakdown of single- and dual-chamber pacemakers and ICDs in each country? How will this change in the coming years?
Cardiac resynchronization therapy (CRT) is on the rise globally, and while the market is largely underpenetrated as of now, CRT devices are expected to experience significant adoption during the forecast period. Which countries are utilizing the devices now? How often will the devices be used in the future? What do Key Opinion Leaders think of these biventricular products?
Changing demographics are driving device implantation. How will risk factors including obesity, hypertension and diabetes affect the global CRM market?
Several major players in the market have already developed next-generation features. What are the most important product features and designs surgeons like about current systems? What features would they like to see in future product iterations? How will the introduction of energy-harvesting and leadless devices impact conventional device sales?
Device reprocessing and recycling is increasingly popular. What do patients think of reusing devices? How will this affect global CRM new-device sales?
Medtronic currently dominates the CRM market. What is their market share in the major global economies and which companies constitute the remainder of the market?
Companies are increasingly reliant on device adoption in emerging markets for continued sales growth. What percent of global profits are from emerging markets? How will this change in the future?
Diagnostic tools and techniques have improved greatly in recent years, driving CRM sales. How will diagnostic improvements continue to increase CRM market revenue?
Market Model Features
Market model features: An interactive Excel forecast model based on primary research interviews with KOLs, physicians, industry participants and distributors is included with this report*. This patient-based model provides diagnosis rates, patient segmentation, treatment rates, procedure volumes, average selling prices, and market values over a 11-year period (2010–2020). The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.
The model offers several valuable perspectives of the cardiac resynchronization therapy market. It includes procedure volumes and market valuations for current and future indications of CRM, including:
• Sick sinus syndrome
• Atrioventricular block
• Primary prevention
• Ventricular tachycardia
• Ventricular fibrillation
*Interactive Excel forecast model only available to clients purchasing a site license or higher.
What Physicians Think
What Do Physicians Think: “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.